Volume 24, Number 11—November 2018
Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014–2017
Highlight and copy the desired format.
|EID||Grassly NC, Wadood M, Safdar RM, Mahamud A, Sutter RW. Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014–2017. Emerg Infect Dis. 2018;24(11):2113-2115. https://dx.doi.org/10.3201/eid2411.180050|
|AMA||Grassly NC, Wadood M, Safdar RM, et al. Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014–2017. Emerging Infectious Diseases. 2018;24(11):2113-2115. doi:10.3201/eid2411.180050.|
|APA||Grassly, N. C., Wadood, M., Safdar, R. M., Mahamud, A., & Sutter, R. W. (2018). Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014–2017. Emerging Infectious Diseases, 24(11), 2113-2115. https://dx.doi.org/10.3201/eid2411.180050.|
Pakistan began using inactivated poliovirus vaccine alongside oral vaccine in mass campaigns to accelerate eradication of wild-type poliovirus in 2014. Using case-based and environmental surveillance data for January 2014–October 2017, we found that these campaigns reduced wild-type poliovirus detection more than campaigns that used only oral vaccine.
Routine immunization with >1 dose of inactivated poliovirus vaccine (IPV) in all countries using oral poliovirus vaccine (OPV) was recommended by the World Health Organization (WHO) in November 2012, before the global withdrawal of the serotype 2 component from OPV (1). IPV has also been used since 2014 in mass campaigns to help interrupt wild poliovirus transmission and stop serotype 2 vaccine-derived poliovirus (VDPV2) outbreaks. The IPV supply was severely constrained during 2016–2017; only 2 manufacturers supply the United Nations Children’s Fund, and their failure to produce the expected bulk product has meant that only about half the awarded quantities were supplied (2). As a result of these unplanned reductions in IPV supply, countries have delayed the introduction of IPV to routine immunization or faced stockouts, and mass campaigns with IPV in response to VDPV2 are no longer recommended by WHO (3). Nonetheless, where possible, IPV continues to be used in mass campaigns for outbreak response; for example, Pakistan, Afghanistan, Nigeria, and Syria all used IPV in mass campaigns in 2017.
Given that IPV supply constraints are likely to continue until at least the end of 2018, it is crucial that available IPV be optimally allocated between routine immunization and mass campaigns. We recently published estimates of the impact of OPV mass campaigns with and without the inclusion of IPV in Nigeria and Pakistan during January 2014–April 2016 (4). These estimates demonstrated a reduction in the incidence of poliomyelitis and detection of poliovirus in the environment after campaigns that used IPV in Nigeria but not in Pakistan, where statistical power was limited. We have now updated these estimates in Pakistan for January 2014–October 2017, thereby including a longer period of surveillance and additional campaigns during a period when wild-type 1 poliovirus has been circulating (Technical Appendix). We find evidence of an impact of campaigns that used IPV alongside OPV (bivalent, trivalent, or monovalent) on the incidence of poliomyelitis caused by wild-type poliovirus (incidence rate ratio [IRR] for 90 days after compared with before the campaign, IRR 0.62, 90% bootstrap CI 0.23–1.14), and a significant impact on the detection of this virus in environmental samples (prevalence ratio [PR] 0.63, 90% CI 0.47–0.81) (Figure; Technical Appendix Table). The effect of campaigns using only bivalent OPV was less than the effect of campaigns that included IPV (IRR for poliomyelitis 0.79 [90% CI 0.64–0.98] and PR for environmental detection 0.92 [90% CI 0.83–1.00] for the 90 days after compared with before the campaign); this difference was statistically significant for detection of poliovirus in the environment (bootstrap p values 0.239 comparing the IRRs and 0.005 comparing the PRs for campaigns with and without IPV). We did not update estimates for Nigeria because only 2 campaigns using IPV occurred during April 2016–October 2017, in areas with very limited VDPV2 detection.
Several caveats relate to this analysis, reflecting its observational nature, reliance on routinely collected data, and lack of randomization. Campaigns that included IPV may have been implemented with different standards and, potentially, greater coverage, although data supporting this assertion have not been presented. It is often assumed that campaigns including IPV would have lower coverage because IPV must be administered by trained healthcare staff from fixed points rather than in house-to-house campaigns (5). Furthermore, these findings may not apply to more recent serotype-2 vaccine-derived poliovirus outbreaks, which have occurred in countries without recent use of a serotype-2–containing oral vaccine, thereby limiting boosting of mucosal immunity by IPV to older cohorts.
In conclusion, these updated estimates from Pakistan provide support for including IPV in mass campaigns with OPV to reduce poliovirus transmission, in agreement with results from Nigeria. Intradermal administration of a 1/5 fractional dose may allow dose sparing during these campaigns while maintaining comparable immunogenicity (6). These findings are informing discussions about the role of IPV in stopping the last remaining chains of wild-type 1 poliovirus transmission, responding to VDPV2 outbreaks, and protecting children who have not received vaccine containing serotype 2.
Dr. Grassly is a professor of vaccine epidemiology in the department of infectious disease epidemiology at Imperial College London, London, UK. His primary research interests are the epidemiology of enteric viruses and immune response to infection and vaccination.
We thank all those involved in the extensive efforts to implement clinical and environmental surveillance in Pakistan.
This work was supported by research grants from the World Health Organization (2013/363982) and the Bill and Melinda Gates Foundation (OPP1099374).
- World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012—conclusions and recommendations. Wkly Epidemiol Rec. 2013;88:1–16.https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23311010&dopt=Abstract
- Lewis I, Ottosen A, Rubin J, Blanc DC, Zipursky S, Wootton E. A supply and demand management perspective on the accelerated global introductions of inactivated poliovirus vaccine in a constrained supply market. J Infect Dis. 2017;216(suppl_1):S33–9.
- Global Polio Eradication Initiative. Standard operating procedures: responding to a poliovirus event or outbreak. V2.3 01; 2017 [cited 2017 May 7]. http://www.polioeradication.org
- Shirreff G, Wadood MZ, Vaz RG, Sutter RW, Grassly NC. Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014–April 2016. Emerg Infect Dis. 2017;23:258–63.
- Pervaiz A, Mbaeyi C, Baig MA, Burman A, Ahmed JA, Akter S, et al. Fractional-dose inactivated poliovirus vaccine campaign—Sindh Province, Pakistan, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:1295–9.
- Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D, Jarrahian C, et al. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization. J Infect Dis. 2017;216(suppl_1):S161–7.
FigureCite This Article
Original Publication Date: 9/25/2018
- Page created: October 16, 2018
- Page last updated: October 16, 2018
- Page last reviewed: October 16, 2018
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)